AEON Biopharma, Inc.

AEON Biopharma, Inc. (Nasdaq: AEON) is a clinical-stage biopharmaceutical company developing botulinum toxin complex therapeutics for a range of medical indications. The company reached the public markets through its merger with Priveterra Acquisition Corp, a blank-check vehicle sponsored by Priveterra Sponsor, LLC that completed its IPO in 2021. AEON filed a Form 10-Q with the SEC on July 21, 2023, marking an early reporting period as a newly combined public company operating in the specialty pharmaceuticals and biotechnology sector. For full filing history, sponsor details, warrant data, and real-time SPAC analytics on AEON and hundreds of other transactions, sign up for complete access at SpacDesk.